Trovagene (TROV) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. SBUX
10. AXP

Go back to Trovagene (TROV) Misses Q4 EPS by 1c

TrovaGene (TROV) Commercial Program Underway With A Key Advantage - Piper Jaffray

March 11, 2016 11:02 AM EST

Piper Jaffray analyst, William Quirk, believes Trovagene Inc's (NASDAQ: TROV) collection advantage (~100mL of urine vs. ~10mL of blood) is a competitive advantage that will allow it to take share and eventually approach value based pricing. PT drops $1 to $8 but the Overweight rating remains.

Adjusted EPS of ($0.26) was unfavorable to consensus of ($0.25). Trovagene is making progress on the reimbursement front and now has 150M covered lives. Management reiterated upcoming publications and data presentations as well as expanded panels... More